Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex. Materials and Methods This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea. Results A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits. Conclusion Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.
Abstract
Purpose The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex. Materials and Methods This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea. Results A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits. Conclusion Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.
참고문헌 (29)
- Ozdemir BC, "Sex differences in efficacy and toxicity of systemic treatments : an undervalued issue in the era of precision oncology", J Clin Oncol, 36, pp.2680~2683 (2018)
- Soldin OP, "Sex differences in drug disposition", J Biomed Biotechnol, 2011, pp.187103~ (2011)
- Ozdemir BC, "Sex and gender differences in anticancer treatment toxicity : a call for revisiting drug dosing in oncology", Endocrinology, 163, pp.bqac058~ (2022)
- Unger JM, "Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials", J Clin Oncol, 40, pp.1474~1486 (2022)
- Kim HI, "Sex differences in cancer : epidemiology, genetics and therapy", Biomol Ther(Seoul), 26, pp.335~342 (2018)
- Milano G, "Influence of sex and age on fluorouracil clearance", J Clin Oncol, 10, pp.1171~1175 (1992)
- Sloan JA, "Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer", J Clin Oncol, 20, pp.1491~1498 (2002)
- Schwab M, "Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity : a prospective clinical trial by the German 5-FU Toxicity Study Group", J Clin Oncol, 26, pp.2131~2138 (2008)
- Chansky K, "Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma", Cancer, 103, pp.1165~1171 (2005)
- Singh S, "Influence of sex on toxicity and treatment outcome in small-cell lung cancer", J Clin Oncol, 23, pp.850~856 (2005)
- Pignon JP, "Lung adjuvant cisplatin evaluation : a pooled analysis by the LACE Collaborative Group", J Clin Oncol, 26, pp.3552~3559 (2008)
- Kim JH, "The impact of systematic assessment for adverse events on uns-cheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy : a retrospective multicenter study", Cancer Med, 11, pp.705~714 (2022)
- Wagner AD, "Sex and adverse events of adjuvant chemotherapy in colon cancer : an analysis of 34 640 patients in the ACCENT database", J Natl Cancer Inst, 113, pp.400~407 (2021)
- Yamada Y, "Sex differences in the safety of S-1 plus oxaliplatin and S-1 plus cisplatin for patients with metastatic gastric cancer", Cancer Sci, 110, pp.2875~2883 (2019)
- Wakelee HA, "Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594", J Thorac Oncol, 1, pp.441~446 (2006)
- Yamamoto H, "Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel", Oncology, 75, pp.169~174 (2008)
- Borghaei H, "Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy", Lung Cancer, 119, pp.112~119 (2018)
- Krzyzanowska MK, "Remote, proactive, telephone based management of toxicity in outpatients during adjuvant or neoadjuvant chemotherapy for early stage breast cancer : pragmatic, cluster randomised trial", BMJ, 375, pp.e066588~ (2021)
- Friese CR, "Treatment-associated toxicities reported by patients with early-stage invasive breast cancer", Cancer, 123, pp.1925~1934 (2017)
- Abdel-Rahman O, "Predictors of toxicity-related hospitalization in four randomized studies of 5-fluorouracil-based chemotherapy in metastatic colorectal cancer", Int J Colorectal Dis, 34, pp.675~680 (2019)
- Bonadonna G, "Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer : the results of 20 years of follow-up", N Engl J Med, 332, pp.901~906 (1995)
- Port RE, "Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance", Oncology, 48, pp.277~281 (1991)
- Meulendijks D, "Clinical relevance of DPYD variants c. 1679T>G, c. 1236G>A", HapB3, and c. 1601G>A as predictors of severe fluoropyrimidine-associated toxicity : a systematic review and meta-analysis of individual patient data, 2015, pp.16, 1639~1650
- Ryberg D, "Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients", Cancer Res, 54, pp.5801~5803 (1994)
- Mollerup S, "Sex differences in lung CYP1A1 expression and DNA adduct levels among lung cancer patients", Cancer Res, 59, pp.3317~3320 (1999)
- Joerger M, "Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors", Clin Cancer Res, 12, pp.2150~2157 (2006)
- Nicolson TJ, "Gender differences in drug toxicity", Trends Pharmacol Sci, 31, pp.108~114 (2010)
- Franconi F, "Gender differences in drug responses", Pharmacol Res, 55, pp.81~95 (2007)
- Cristina V, "Association of patient sex with chemotherapy-related toxic effects : a retrospective analysis of the PETACC-3 trial conducted by the EORTC Gastrointestinal Group", JAMA Oncol, 4, pp.1003~1006 (2018)